Development of porcine circovirus 2 (PCV2) open reading frame 2 DNA vaccine with different adjuvants and comparison with commercial PCV2 subunit vaccine in an experimental challenge.

about

Development of porcine circovirus 2 (PCV2) open reading frame 2 DNA vaccine with different adjuvants and comparison with commercial PCV2 subunit vaccine in an experimental challenge.

Item

http://www.wikidata.org/entity/Q47102234

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Development of porcine circovi ...... in an experimental challenge.

@en

Development of porcine circovirus 2

@nl

type

Item

label

Development of porcine circovi ...... in an experimental challenge.

@en

Development of porcine circovirus 2

@nl

prefLabel

Development of porcine circovi ...... in an experimental challenge.

@en

Development of porcine circovirus 2

@nl

P1476

Development of porcine circovi ...... in an experimental challenge.

@en

P2093

Changhoon Park

http://www.w3.org/2001/XMLSchema#string

Chanhee Chae

http://www.w3.org/2001/XMLSchema#string

Ikjae Kang

http://www.w3.org/2001/XMLSchema#string

Jiwoon Jeong

http://www.w3.org/2001/XMLSchema#string

Kyuhyung Choi

http://www.w3.org/2001/XMLSchema#string

Su-Jin Park

http://www.w3.org/2001/XMLSchema#string

P2860

Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease.

DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs.

Development and use of a multiplex real-time quantitative polymerase chain reaction assay for detection and differentiation of Porcine circovirus-2 genotypes 2a and 2b in an epidemiological survey.

Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge.

Studies on porcine circovirus type 2 vaccination of 5-day-old piglets.

A review of porcine circovirus 2-associated syndromes and diseases.

DNA vaccines: recent developments and future possibilities.

Optimized dispersion of nanoparticles for biological in vitro and in vivo studies.

Targeting the porcine immune system--particulate vaccines in the 21st century.

Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2).

P304

171-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28725106

http://www.w3.org/2001/XMLSchema#string

P932

5508387

http://www.w3.org/2001/XMLSchema#string